Date:_____2022/11/25_____

| Υo | ur Name:Jua | ın Yan | | | |
|-----------------|---|---|--|-----|--|
| | nuscript Title:Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case | | | | |
| re | oort and review of the liter | ature | | | |
| Ma | anuscript number (if knowr | n): | | | |
| | | | | | |
| rel pa to | ated to the content of you rties whose interests may l transparency and does not | r manuscript. "Related" mea be affected by the content o | relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. | | |
| | e following questions apply anuscript only. | y to the author's relationshi | ps/activities/interests as they relate to the current | | |
| to | the epidemiology of hyper | - | defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript. | | |
| | item #1 below, report all su e time frame for disclosure | | d in this manuscript without time limit. For all other iten | ıs, | |
| | | Name all entities with | Specifications/Comments | | |
| | | whom you have this | (e.g., if payments were made to you or to your | | |
| | | relationship or indicate | institution) | | |
| | | none (add rows as | | | |
| | | needed) Time frame: Since the initial | planning of the work | | |
| | All support for the present | X None | planning of the work | | |
| | manuscript (e.g., funding, | XNone | | | |
| | provision of study materials, | | | | |
| | medical writing, article | | | | |
| | processing charges, etc.) | | | | |
| | No time limit for this item. | | | | |
| | | | | | |
| | | | | | |
| | Cuanta au agutus sta form | Time frame: past | 36 months | | |
| | Grants or contracts from any entity (if not indicated | X None | | | |
| | in item #1 above). | | | | |
| | Royalties or licenses | X None | | | |
| | | XNone | | | |
| | | | | | |
| | Consulting foos | V None | | | |

| 5 | Payment or honoraria for | XNone | |
|-----|---|-------------------------------|-------------|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | - | | |
| 7 | Support for attending meetings and/or travel | X None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X None | |
| | | | |
| | writing, gifts or other | | |
| 42 | services | • | |
| 13 | Other financial or non- financial interests | X None | |
| | imanciai interests | | |
| | | | |
| | | | |
| ום | ease summarize the above c | anflict of interact in the fo | Howing hove |
| PIE | ease summarize the above c | onnict of interest in the 10 | nowing box. |
| | X | | |
| | ^ | | |
| | | | |

| Date: | 2022/ | 11/25 | |
|--|---|---|--|
| Your Name: | Na l | Ma | |
| Manuscript Tit | le:Adv | erse skin reactions induc | zed by sintilimab in advanced lung squamous carcinoma: a case |
| report and revi | iew of the litera | ture | |
| Manuscript nu | mber (if known) | : | |
| related to the oparties whose to transparence relationship/actions | content of your interests may be y and does not estivity/interest, questions apply by. elationships/activity ology of hyperteen if that medications, report all supersections. | manuscript. "Related" me affected by the content necessarily indicate a bia it is preferable that you on to the author's relations ivities/interests should be ension, you should declaration is not mentioned in | hips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive |
| | | Name all entities with whom you have this relationship or indicate none (add rows as | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | | needed) Time frame: Since the init | ial planning of the work |
| manuscript (provision of medical writ processing c | • | XNone | |
| | | | |
| | | Time frame: pa | est 36 months |
| | ntracts from f not indicated pove). | XNone | SC 30 Montals |
| Royalties or | | XNone | |
| Consulting for | ees | XNone | |

4

| 5 | Payment or honoraria for | XNone | |
|-----|---|-------------------------------|-------------|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | - | | |
| 7 | Support for attending meetings and/or travel | X None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X None | |
| | | | |
| | writing, gifts or other | | |
| 42 | services | • | |
| 13 | Other financial or non- financial interests | X None | |
| | imanciai interests | | |
| | | | |
| | | | |
| ום | ease summarize the above c | anflict of interact in the fo | Howing hove |
| PIE | ease summarize the above c | onnict of interest in the 10 | nowing box. |
| | X | | |
| | ^ | | |
| | | | |

| Da | te:2022, | /11/25 | |
|--------------------------------------|--|---|---|
| Yo | ur Name:We | i-Li Qiao | |
| Ma | nuscript Title:Adv | verse skin reactions induced | d by sintilimab in advanced lung squamous carcinoma: a case |
| rep | oort and review of the litera | nture | |
| Ma | nuscript number (if known |): | |
| rel par to rel The ma | ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, at following questions apply inuscript only. The author's relationships/act the epidemiology of hypertedication, even if that medication. | manuscript. "Related" means affected by the content of necessarily indicate a bias. It is preferable that you do not to the author's relationship to the author's relationship to the author's should be the necessarily interests should be the necessarily indicate a bias. | ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | | Time frame: Since the initia | I planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | X None | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | X None | |

| 5 | Payment or honoraria for | XNone | |
|-----|---|-------------------------------|-------------|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | - | | |
| 7 | Support for attending meetings and/or travel | X None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X None | |
| | | | |
| | writing, gifts or other | | |
| 42 | services | • | |
| 13 | Other financial or non- financial interests | X None | |
| | imanciai interests | | |
| | | | |
| | | | |
| ום | ease summarize the above c | anflict of interact in the fo | Howing hove |
| PIE | ease summarize the above c | onnict of interest in the 10 | nowing box. |
| | X | | |
| | ^ | | |
| | | | |

| Da | te:2022 | /11/25 | |
|--------------------------------------|--|---|---|
| | | | |
| Ma | anuscript Title:Adv | verse skin reactions induced | d by sintilimab in advanced lung squamous carcinoma: a case |
| rep | oort and review of the litera | ature | |
| Ma | nuscript number (if known |): | |
| rel par to rel The ma | ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply inuscript only. e author's relationships/activity epidemiology of hypertedication, even if that medication. | manuscript. "Related" means affected by the content of necessarily indicate a bias. It is preferable that you do not to the author's relationship to the author's relationship to the author's should be tension, you should declare cation is not mentioned in the apport for the work reported. | ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | X None | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | X None | |

| 5 | Payment or honoraria for | XNone | |
|-----|---|-------------------------------|-------------|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | - | | |
| 7 | Support for attending meetings and/or travel | X None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X None | |
| | | | |
| | writing, gifts or other | | |
| 42 | services | • | |
| 13 | Other financial or non- financial interests | X None | |
| | imanciai interests | | |
| | | | |
| | | | |
| ום | ease summarize the above c | anflict of interact in the fo | Howing hove |
| PIE | ease summarize the above c | onnict of interest in the 10 | nowing box. |
| | X | | |
| | ^ | | |
| | | | |

| Your Name: | Dai | -Wei Liu | |
|--|--|--|---|
| Manuscript Title | e:Adv | erse skin reactions induce | ed by sintilimab in advanced lung squamous carcinoma: a ca |
| report and revie | | | |
| Manuscript num | | | |
| related to the coparties whose in to transparency relationship/act The following quanuscript only The author's relation the epidemio | ontent of your name of your name of your name of your and does not civity/interest, uestions apply of hypertons of hyperto | manuscript. "Related" mee affected by the content necessarily indicate a bias it is preferable that you do to the author's relationshivities/interests should be | nips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive |
| | • | pport for the work reporte s the past 36 months. Name all entities with whom you have this | Specifications/Comments (e.g., if payments were made to you or to your |
| | | relationship or indicate | institution) |
| | | none (add rows as | |
| | | needed) | |
| | | Time frame: Since the initia | al planning of the work |
| All support fo | r the nresent | X None | |
| manuscript (e | - | | |
| | tudy materials, | | |
| medical writin | • | | |
| processing ch | = | | |
| ' | for this item. | | |
| | | | |
| | | | |
| | | | |
| | | Time frame: pas | it 36 months |
| Grants or con any entity (if in item #1 abo | not indicated | XNone | |
| | | V Name | |
| Royalties or li | censes | XNone | |
| | | | |
| | | | |

| 5 | Payment or honoraria for | XNone | |
|-----|---|-------------------------------|-------------|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | - | | |
| 7 | Support for attending meetings and/or travel | X None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X None | |
| | | | |
| | writing, gifts or other | | |
| 42 | services | • | |
| 13 | Other financial or non- financial interests | X None | |
| | imanciai interests | | |
| | | | |
| | | | |
| ום | ease summarize the above c | anflict of interact in the fo | Howing hove |
| PIE | ease summarize the above c | onnict of interest in the 10 | nowing box. |
| | X | | |
| | ^ | | |
| | | | |

Date:_____2022/11/25_____

| Υo | ur Name:Yu ' | Wang | | |
|------------------------|---|--|--|------|
| Ma | anuscript Title:Adv | verse skin reactions induced | d by sintilimab in advanced lung squamous carcinoma: a | case |
| rep | oort and review of the litera | ture | | |
| Ma | anuscript number (if known) |): | | |
| | | | | |
| rel pa to rel | ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, | manuscript. "Related" mea e affected by the content o necessarily indicate a bias. it is preferable that you do | | |
| | e following questions apply anuscript only. | to the author's relationship | ps/activities/interests as they relate to the <u>current</u> | |
| to me | the epidemiology of hypertoedication, even if that medic | ension, you should declare cation is not mentioned in to poort for the work reported | defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other iter | • |
| | | Name all entities with | Specifications/Comments | |
| | | whom you have this | (e.g., if payments were made to you or to your | |
| | | relationship or indicate | institution) | |
| | | none (add rows as | | |
| | | needed) Time frame: Since the initial | planning of the work | |
| | All support for the present | X None | planning of the work | |
| | manuscript (e.g., funding, | X Notic | | |
| | provision of study materials, | | | |
| | medical writing, article | | | |
| | processing charges, etc.) | | | |
| | No time limit for this item. | | | |
| | | | | |
| | | Time frame: past | 26 months | |
| | Grants or contracts from | X None | 50 months | |
| | any entity (if not indicated | X None | | |
| | in item #1 above). | | | |
| , | Royalties or licenses | X None | | |
| | | | | |
| | | | | |
| | Consulting foor | V Name | | |

| 5 | Payment or honoraria for | XNone | |
|-----|---|-------------------------------|-------------|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | - | | |
| 7 | Support for attending meetings and/or travel | X None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X None | |
| | | | |
| | writing, gifts or other | | |
| 42 | services | • | |
| 13 | Other financial or non- financial interests | X None | |
| | imanciai interests | | |
| | | | |
| | | | |
| ום | ease summarize the above c | anflict of interact in the fo | Howing hove |
| PIE | ease summarize the above c | onnict of interest in the 10 | nowing box. |
| | X | | |
| | ^ | | |
| | | | |

| Da | te:2022/ | /11/25 | | |
|--------------------------------------|--|--|---|--|
| Yo | ur Name:Tin | g-Ting Qiao | | |
| Ma | anuscript Title:Adv | Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case | | |
| rep | report and review of the literature | | | |
| Ma | anuscript number (if known |): | | |
| rel par to rel The ma | ated to the content of your rties whose interests may b transparency and does not ationship/activity/interest, e following questions apply muscript only. e author's relationships/act the epidemiology of hypert edication, even if that medication. | manuscript. "Related" mede affected by the content of necessarily indicate a bias. It is preferable that you do to the author's relationship with the author's relationship with the second because of the content of the content of the work reported the content of th | ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive | |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | |
| | | Time frame: Since the initia | I planning of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | | |
| | | Time frame: past | : 36 months | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | . So months | |
| 3 | Royalties or licenses | XNone | | |
| 4 | Consulting fees | X None | | |

| 5 | Payment or honoraria for lectures, presentations, | XNone | |
|-----|---|-------------------------------|-------------|
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | - | | |
| 7 | Support for attending meetings and/or travel | X None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | X None | |
| | | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X None | |
| | | | |
| | writing, gifts or other | | |
| 42 | services | • | |
| 13 | Other financial or non- financial interests | XNone | |
| | imanciai interests | | |
| | | | |
| | | | |
| -ום | ease summarize the above c | anflict of interact in the fo | llowing hov |
| PIE | ease summanize the above c | onnict of interest in the 10 | nowing box. |
| | X | | |
| | ^ | | |
| | | | |

| Manuscript Title: Adverse skin reactions induced by sintilimab in advanced lung squamous carci report and review of the literature Manuscript number (if known): | at are |
|--|-------------------------|
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below t related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit parties whose interests may be affected by the content of the manuscript. Disclosure represents a comm to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the currimanuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypmedication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all of the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, | at are |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below t related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit parties whose interests may be affected by the content of the manuscript. Disclosure represents a comm to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the curremanuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypmedication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all of the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, | hird |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below t related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit parties whose interests may be affected by the content of the manuscript. Disclosure represents a comm to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the curremanuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypemedication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all of the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, | hird |
| related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit parties whose interests may be affected by the content of the manuscript. Disclosure represents a comm to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the currimanuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypmedication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all of the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, | hird |
| Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, | t pertains ertensive |
| whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, | iner items |
| none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, | |
| needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, | |
| All support for the present manuscript (e.g., funding, provision of study materials, | |
| All support for the present manuscript (e.g., funding, provision of study materials, | |
| manuscript (e.g., funding, provision of study materials, | |
| provision of study materials, | |
| | |
| medical writing, differe | |
| processing charges, etc.) | |
| No time limit for this item. | |
| | |
| | |
| | |
| Time frame: past 36 months | |
| Grants or contracts from any entity (if not indicatedXNone | |
| in item #1 above). | |
| Royalties or licenses X None | |
| | |
| | |
| Consulting fees X_None | |

| 5 | Payment or honoraria for lectures, presentations, | XNone | |
|-----|---|-------------------------------|-------------|
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | - | | |
| 7 | Support for attending meetings and/or travel | X None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | X None | |
| | | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X None | |
| | | | |
| | writing, gifts or other | | |
| 42 | services | • | |
| 13 | Other financial or non- financial interests | XNone | |
| | imanciai interests | | |
| | | | |
| | | | |
| -ום | ease summarize the above c | anflict of interact in the fo | llowing hov |
| PIE | ease summanize the above c | onnict of interest in the 10 | nowing box. |
| | X | | |
| | ^ | | |
| | | | |

case

| Da | te:2022/ | /11/25 | | |
|-------------------------------|--|--|---|--|
| Yo | ur Name:Mac | o-Dong Zheng | | |
| Ma | nuscript Title:Adv | verse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a cas | | |
| rep | oort and review of the litera | ture | | |
| Ma | nuscript number (if known) |): | | |
| rel to rel The ma | ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, ationship/activity/interest, at following questions apply inuscript only. The author's relationships/act the epidemiology of hypertedication, even if that medication, even if that medication. | manuscript. "Related" means affected by the content of the author's relationship ivities/interests should be the content of th | ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive | |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | |
| | | Time frame: Since the initial | Inlanning of the work | |
| 1 | All support for the present manuscript (e.g., funding, | XNone | | |
| | provision of study materials, medical writing, article | | | |
| | processing charges, etc.) No time limit for this item. | | | |
| | no time mine for this item. | | | |
| | | | | |
| | | Time frame: past | 36 months | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | | |
| 3 | Royalties or licenses | XNone | | |
| | | | | |
| 4 | Consulting fees | XNone | | |

| 5 | Payment or honoraria for lectures, presentations, | XNone | |
|-----|---|-------------------------------|-------------|
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | - | | |
| 7 | Support for attending meetings and/or travel | X None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | X None | |
| | | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X None | |
| | | | |
| | writing, gifts or other | | |
| 42 | services | • | |
| 13 | Other financial or non- financial interests | XNone | |
| | imanciai interests | | |
| | | | |
| | | | |
| -ום | ease summarize the above c | anflict of interact in the fo | llowing hov |
| PIE | ease summanize the above c | onnict of interest in the 10 | nowing box. |
| | X | | |
| | ^ | | |
| | | | |